Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.
about
Advances of gene therapy for primary immunodeficienciesCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaGene therapy for primary immunodeficienciesUpdate on the hyper immunoglobulin M syndromesEfficient infection of primitive hematopoietic stem cells by modified adenovirus.Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.Update on gene therapy for immunodeficiencies.X-linked immunodeficiency with hyper-IgM (XHIM).CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.Prospects for CD40-directed experimental therapy of human cancer.Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligandEnhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine productionHuman CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expressionCD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.A genome editing primer for the hematologistThe role of CD40 and CD154/CD40L in dendritic cells.Physiological and tissue-specific vectors for treatment of inherited diseases.Modern management of primary B-cell immunodeficiencies.The hyper IgM syndromes.Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again.Gene therapy for primary immunodeficiencies: current status and future prospects.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing.Evolving Gene Therapy in Primary Immunodeficiency.A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences.A T cell-specific enhancer of the human CD40 ligand gene.Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter.How realistic is cutaneous gene therapy?Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned.From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders.
P2860
Q26742031-48B72191-F1AE-4315-B4E0-40AACC5F570DQ26800814-771D9165-5BC8-43C7-90AB-C9187EDD292AQ26864856-BA754878-546C-4EDA-B711-DEE81130F0F6Q28972255-F96474E2-7CAE-4D38-B5AB-F2754F9F2C83Q33182157-2F2A3F15-EDD5-49EB-95C9-39733D3B0226Q33383530-51F1193E-A07A-4EA3-9C29-899F31AECE44Q33798427-192C6FD0-FD63-47A4-B44D-1E061E7B8451Q33938151-3D737FC0-2202-4D23-8359-EB8228B285E8Q34266298-0183F4DA-DBBF-4423-9AC0-01F3AA818203Q34401676-5A4ABC66-E770-4378-8697-765C2156A478Q35028895-9C8E6BBD-368E-498F-9A72-E04501CBA20EQ35346307-8D956A33-3B42-4182-8C62-C9B6575F5C74Q35399334-56757A90-0CEC-46AC-AB3D-B6AA36385FE3Q35839888-BD3A232E-187A-4C8B-B845-12539741F12BQ35868342-D0349983-73B9-425F-A6D6-DDC467FDAE12Q36002320-232B0D03-A3F7-47A4-9F28-7FA89886462BQ36942027-BC6B782F-C807-4722-B837-3D55E001537EQ37518524-7DD7058D-C26F-4E0C-AFE7-5864F428119BQ37801839-FDAA0A49-A404-4858-9725-7C102E7F6DC6Q37962045-C823CAB1-948E-4EE6-81EA-F8FEC64B76CCQ38116775-63BD55B5-9C91-40AC-9732-14C6C86ED5D4Q38168950-3A3FB363-6B50-464D-B01B-F51EE258C087Q38213501-073C7F56-E167-4AF1-BFBA-0C6C43E037CAQ38289442-15670B35-C222-4674-A09A-AA12A52790CCQ39166979-7F3FC5FB-F5E2-4626-A241-FB8D5D149F1AQ39214064-061ECF8F-23DA-4D20-A40C-D423C5A14FC1Q39627668-B2CB13EB-546F-4689-826E-583DF231E31DQ40761786-EC6AF164-3101-4FC4-9BF5-80FE84DB75CFQ41533331-C1787817-987C-4EC9-BF92-05A9FD900161Q45863128-06534419-3BFD-4D7A-9130-7BBBBDE2943DQ45873930-28672155-53DA-4D11-8760-E3E92AA663C9Q53061634-A905F95F-5699-4434-8DDD-AB6FC2497DA2
P2860
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@en
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@nl
type
label
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@en
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@nl
prefLabel
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@en
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@nl
P2093
P2860
P356
P1433
P1476
Thymic lymphoproliferative dis ...... ency by gene transfer in mice.
@en
P2093
Brenner MK
Pattengale PK
Sangster MY
Woodland DL
P2860
P2888
P304
P356
10.1038/3233
P407
P577
1998-11-01T00:00:00Z
P6179
1040840783